Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

  • Technology appraisal guidance
  • TA725
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence